PE20211756A1 - FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß - Google Patents
FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFßInfo
- Publication number
- PE20211756A1 PE20211756A1 PE2021000893A PE2021000893A PE20211756A1 PE 20211756 A1 PE20211756 A1 PE 20211756A1 PE 2021000893 A PE2021000893 A PE 2021000893A PE 2021000893 A PE2021000893 A PE 2021000893A PE 20211756 A1 PE20211756 A1 PE 20211756A1
- Authority
- PE
- Peru
- Prior art keywords
- polymorphic forms
- tgfß
- inhibitor
- novel polymorphic
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/18—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invencion se refiere a formas amorfas y polimorficas cristalinas novedosas de 4-(2-(5-cloro-2-fluorofenil)-5-isopropilpiridin-4-ilamino)-N-(1,3- dihidroxipropan-2-il)nicotinamida y a metodos para su preparacion; la invencion tambien se refiere a composiciones farmaceuticas que contienen al menos una forma polimorfica y al uso terapeutico o profilactico de tales composiciones y formas polimorficas. Este compuesto es util en el tratamiento de crecimiento celular anormal, tal como cancer, en mamiferos
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782411P | 2018-12-20 | 2018-12-20 | |
US201962930170P | 2019-11-04 | 2019-11-04 | |
PCT/IB2019/060944 WO2020128850A1 (en) | 2018-12-20 | 2019-12-17 | Novel polymorphic forms of a tgfβ inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211756A1 true PE20211756A1 (es) | 2021-09-07 |
Family
ID=69159846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000893A PE20211756A1 (es) | 2018-12-20 | 2019-12-17 | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß |
Country Status (20)
Country | Link |
---|---|
US (1) | US20200199104A1 (es) |
EP (1) | EP3898591A1 (es) |
JP (1) | JP2022513925A (es) |
KR (1) | KR20210104808A (es) |
CN (1) | CN113272279A (es) |
AU (1) | AU2019404250B2 (es) |
BR (1) | BR112021010577A2 (es) |
CA (1) | CA3123829A1 (es) |
CL (1) | CL2021001602A1 (es) |
CO (1) | CO2021007875A2 (es) |
CR (1) | CR20210334A (es) |
EC (1) | ECSP21044734A (es) |
IL (1) | IL284226A (es) |
MA (1) | MA54526A (es) |
MX (1) | MX2021007251A (es) |
PE (1) | PE20211756A1 (es) |
SG (1) | SG11202105763SA (es) |
TW (1) | TWI743631B (es) |
UY (1) | UY38517A (es) |
WO (1) | WO2020128850A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022130206A1 (en) * | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
WO2022229846A1 (en) * | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2813875T3 (es) * | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
-
2019
- 2019-12-17 KR KR1020217022254A patent/KR20210104808A/ko not_active Application Discontinuation
- 2019-12-17 SG SG11202105763SA patent/SG11202105763SA/en unknown
- 2019-12-17 EP EP19835785.7A patent/EP3898591A1/en not_active Withdrawn
- 2019-12-17 CA CA3123829A patent/CA3123829A1/en active Pending
- 2019-12-17 MX MX2021007251A patent/MX2021007251A/es unknown
- 2019-12-17 MA MA054526A patent/MA54526A/fr unknown
- 2019-12-17 JP JP2021534623A patent/JP2022513925A/ja not_active Withdrawn
- 2019-12-17 BR BR112021010577-8A patent/BR112021010577A2/pt unknown
- 2019-12-17 AU AU2019404250A patent/AU2019404250B2/en active Active
- 2019-12-17 WO PCT/IB2019/060944 patent/WO2020128850A1/en unknown
- 2019-12-17 PE PE2021000893A patent/PE20211756A1/es unknown
- 2019-12-17 CR CR20210334A patent/CR20210334A/es unknown
- 2019-12-17 CN CN201980086144.4A patent/CN113272279A/zh active Pending
- 2019-12-17 US US16/716,696 patent/US20200199104A1/en active Pending
- 2019-12-18 UY UY0001038517A patent/UY38517A/es unknown
- 2019-12-19 TW TW108146622A patent/TWI743631B/zh active
-
2021
- 2021-06-16 CO CONC2021/0007875A patent/CO2021007875A2/es unknown
- 2021-06-17 CL CL2021001602A patent/CL2021001602A1/es unknown
- 2021-06-18 EC ECSENADI202144734A patent/ECSP21044734A/es unknown
- 2021-06-20 IL IL284226A patent/IL284226A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113272279A (zh) | 2021-08-17 |
US20200199104A1 (en) | 2020-06-25 |
MX2021007251A (es) | 2021-07-15 |
WO2020128850A1 (en) | 2020-06-25 |
CR20210334A (es) | 2021-07-14 |
TWI743631B (zh) | 2021-10-21 |
TW202039462A (zh) | 2020-11-01 |
JP2022513925A (ja) | 2022-02-09 |
CL2021001602A1 (es) | 2022-01-21 |
IL284226A (en) | 2021-08-31 |
UY38517A (es) | 2020-07-31 |
KR20210104808A (ko) | 2021-08-25 |
BR112021010577A2 (pt) | 2021-08-24 |
EP3898591A1 (en) | 2021-10-27 |
AU2019404250A1 (en) | 2021-07-01 |
SG11202105763SA (en) | 2021-07-29 |
ECSP21044734A (es) | 2021-07-30 |
MA54526A (fr) | 2022-03-30 |
AU2019404250B2 (en) | 2022-12-22 |
CO2021007875A2 (es) | 2021-07-19 |
CA3123829A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600166A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer | |
PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
MX2018008131A (es) | Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma. | |
PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
AR084032A1 (es) | Compuesto biciclico | |
AR106612A1 (es) | Sales, formas cristalinas y composiciones farmacéuticas de 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrilo como inhibidor de demetilasa 1 específica de lisina | |
BR112015007937A2 (pt) | formas cristalinas de um inibidor de fator xia | |
EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
PE20161437A1 (es) | Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
MY194364A (en) | Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof | |
TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
BR112022002772A2 (pt) | Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso |